- A Hexanuclear Cadmium Metal–Organic Framework Exhibiting Dual Mechanisms to Trigger a Fluorescence-Quenching Response toward Iron(III) Ions
-
A hexanuclear CdII metal–organic framework (1) based on 4-(1H-pyrazole-4-carboxamido)benzoic acid (H2L) and featuring a three-dimensional microporous framework was synthesized. Notably, 1 shows a unique fluorescence-quenching response toward Fe3+ ions with high selectivity and sensitivity (Stern–Volmer constant KSV = 2.07 × 104 m–1). The response is attributable to the coaction of absorption competition and energy-transfer (ET) mechanism. Furthermore, spectral analysis indicates that the energy-transfer mechanism makes the dominant contribution to the fluorescence quenching of 1.
- Li, Long-Sheng,Wang, Xi,Jia, Yan-Yuan,Xu, Shi-Xian,Yu, Mei-Hui,Zhang, Ying-Hui
-
-
Read Online
- DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES
-
The application describes dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.
- -
-
Page/Page column 39; 268-269
(2020/01/24)
-
- Preparation method of key intermediate 2 for synthesizing baricitinib
-
The invention relates to a preparation method of a key intermediate 2 for synthesizing baricitinib. The preparation method comprises the following process steps: respectively synthesizing an intermediate A, an intermediate B, an intermediate D and the key intermediate 2. The preparation method has the advantages that commercially available raw materials, i.e. 1H-pyrazole-4-formic acid (SM1), ethylcyanoacetate (SM2), 2-bromo-1,1-diethoxyethane (SM3) and formamidine acetate ( SM4) are used as starting materials, and the key intermediate 2 is obtained after only four steps of chemical reactionsare carried out; the use of starting materials such as 4-chloropyrrolo[2,3-d]pyrimidine and pyrazol borate which are high in material cost is avoided, and the production cost of the key intermediate 2is lowered.
- -
-
Paragraph 0075; 0076; 0093; 0105
(2018/04/28)
-
- PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME
-
Provided herein are pyrazole compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL and/or FAAH. Furthermore, the subject compounds and compositions are useful for the treatment of, for example, pain.
- -
-
Paragraph 00190
(2017/07/14)
-
- Therapeutic Compounds
-
Compounds of formula I or pharmaceutically acceptable salts thereof: wherein R1, R2, R3 and R4 are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
- -
-
Page/Page column 26
(2011/04/25)
-
- Therapeutic Compounds
-
Compounds of formula I or pharmaceutically acceptable salts thereof: wherein R1, R2, R3 and R4 are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
- -
-
Page/Page column 27
(2008/06/13)
-
- Substituted N-acyl-2-aminothiazoles
-
There are presented compounds of the formula or a pharmaceutically acceptable salt thereof, which are useful in the treatment of diabetes, diabetic retinopathy, asthma and diarrhea.
- -
-
Page/Page column 8
(2010/02/15)
-